BioLineRx Announces Q3 EPS of 0c, Unchanged from Last Year
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 24 2025
0mins
Q3 Revenue Decline: BioLineRx reported a Q3 revenue of $427k, a significant drop from $4.121M in the same period last year.
Joint Venture Announcement: The company established a joint venture with Hemispherian to expand its cancer treatment pipeline, focusing on glioblastoma alongside its ongoing PDAC program.
GLIX1 Development: Hemispherian's lead asset, GLIX1, targets DNA repair mechanisms in cancer cells and has shown strong efficacy in pre-clinical models.
Upcoming Clinical Trials: BioLineRx plans to initiate a Phase 1/2a first-in-human study for GLIX1 in Q1 of next year while continuing pre-clinical activities for potential trials in other cancers.
Analyst Views on BLRX
Wall Street analysts forecast BLRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLRX is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.963
Low
12.00
Averages
12.00
High
12.00
Current: 2.963
Low
12.00
Averages
12.00
High
12.00
About BLRX
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
